Evotec inks li­cense agree­ment with J&J; On­colyt­ic virus biotech prices $15M IPO

Drug dis­cov­ery and de­vel­op­ment play­er Evotec en­tered an­oth­er li­cens­ing deal with Big Phar­ma — this time with J&J’s Janssen.

The com­pa­nies put out word that they en­tered in­to a strate­gic col­lab­o­ra­tion and li­cense agree­ment with each oth­er that fo­cus­es on tar­get­ed im­mune-based can­cer ther­a­pies, to be com­mer­cial­ized by Janssen.

Ac­cord­ing to a state­ment, the col­lab­o­ra­tion will hinge on Evotec’s in­te­grat­ed drug dis­cov­ery and man­u­fac­tur­ing ca­pa­bil­i­ties. Dur­ing the pre-clin­i­cal R&D phase, the com­pa­nies will col­lab­o­rate close­ly — and then Janssen will take on full re­spon­si­bil­i­ty for both clin­i­cal de­vel­op­ment and com­mer­cial­iza­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER